Global Retirement Partners LLC Boosts Stock Position in Novartis AG $NVS

Global Retirement Partners LLC raised its position in shares of Novartis AG (NYSE:NVS) by 154.1% during the 4th quarter, Holdings Channel reports. The firm owned 29,730 shares of the company’s stock after buying an additional 18,032 shares during the quarter. Global Retirement Partners LLC’s holdings in Novartis were worth $4,099,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in NVS. Brighton Jones LLC grew its stake in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares during the last quarter. AQR Capital Management LLC grew its stake in Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after purchasing an additional 11,444 shares during the last quarter. Empowered Funds LLC purchased a new stake in Novartis during the 1st quarter valued at about $1,764,000. Sivia Capital Partners LLC boosted its stake in shares of Novartis by 48.0% in the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after buying an additional 2,581 shares during the last quarter. Finally, Schnieders Capital Management LLC. purchased a new stake in shares of Novartis in the second quarter worth about $202,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

NVS has been the topic of a number of recent research reports. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research note on Thursday, March 19th. Morgan Stanley upped their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. TD Cowen restated a “hold” rating on shares of Novartis in a research note on Tuesday, February 17th. Finally, Citigroup restated a “buy” rating on shares of Novartis in a research note on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novartis has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Stock Performance

NYSE NVS opened at $151.85 on Friday. The stock has a market capitalization of $289.74 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 2.64 and a beta of 0.46. Novartis AG has a twelve month low of $111.06 and a twelve month high of $170.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The stock has a 50-day moving average of $150.10 and a 200 day moving average of $145.80.

Novartis (NYSE:NVS) last released its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The business had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.28 EPS. Sell-side analysts anticipate that Novartis AG will post 8.84 EPS for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.